GeneDx investors face August 3, 2026 lead plaintiff deadline in securities fraud class action
DJS Law Group said the proposed case covers GeneDx share purchases from April 16, 2025 to May 4, 2026 and alleges misleading statements about margins and earnings outlook under U.S. securities law.
DJS Law Group said purchasers of GeneDx Holdings Corp. shares between April 16, 2025 and May 4, 2026 have until August 3, 2026 to seek appointment as lead plaintiff in a proposed securities fraud class action. The complaint alleges GeneDx violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by making false or misleading statements to the market. According to the notice, GeneDx later reported a drop in adjusted gross margin in the first quarter of 2026 and lowered its projected full-year earnings, which the complaint says showed its public statements were false and materially misleading throughout the class period. Investors do not need to serve as lead plaintiff to share in any potential recovery, according to the firm.
- lead plaintiff: A representative investor who seeks to direct a proposed class action on behalf of other class members.
- securities fraud class action: A lawsuit brought on behalf of investors alleging materially false or misleading statements under securities laws.
- Rule 10b-5: An SEC anti-fraud rule that prohibits materially false or misleading statements in connection with securities trading.